PROTAGONIST THERAPEUTICS, INC. Financials Protagonist Therapeutics, Inc.
Equities
PTGX
US74366E1029
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 25.15 USD | +1.99% |
|
-1.80% | +9.68% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 191.8 | 867.3 | 1,632 | 536.8 | 1,323 | 1,466 | - | - |
| Enterprise Value (EV) 1 | 68.58 | 561.4 | 1,305 | 411 | 1,136 | 1,078 | 828.2 | 1,466 |
| P/E ratio | -2.37 x | -10.5 x | -12.6 x | -4.2 x | -16.5 x | 35.1 x | -31.1 x | -31.3 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 830 x | 30.3 x | 59.7 x | 20.2 x | 22 x | 7.06 x | 12.2 x | 10.1 x |
| EV / Revenue | 297 x | 19.6 x | 47.7 x | 15.5 x | 18.9 x | 5.19 x | 6.91 x | 10.1 x |
| EV / EBITDA | - | -8.81 x | -10.4 x | - | -12.3 x | -7.49 x | 9.41 x | - |
| EV / FCF | -1.62 x | -7.7 x | -12 x | -3.77 x | -16 x | 6.09 x | -24 x | -18.8 x |
| FCF Yield | -61.8% | -13% | -8.35% | -26.5% | -6.24% | 16.4% | -4.17% | -5.32% |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 27,206 | 43,019 | 47,728 | 49,198 | 57,678 | 58,275 | - | - |
| Reference price 2 | 7.050 | 20.16 | 34.20 | 10.91 | 22.93 | 25.15 | 25.15 | 25.15 |
| Announcement Date | 3/10/20 | 3/10/21 | 2/28/22 | 3/15/23 | 2/27/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.231 | 28.63 | 27.36 | 26.58 | 60 | 207.5 | 119.8 | 145.6 |
| EBITDA 1 | - | -63.73 | -125 | - | -92.68 | -144 | 88 | - |
| EBIT 1 | -80.52 | -64.52 | -125.8 | -131.4 | -93.65 | 40.67 | -6.928 | -44.08 |
| Operating Margin | -34,857.58% | -225.36% | -460.01% | -494.24% | -156.09% | 19.6% | -5.78% | -30.27% |
| Earnings before Tax (EBT) 1 | -77.88 | -64.84 | -125.6 | -127.4 | -78.96 | 83.42 | 1.034 | -45.28 |
| Net income 1 | -77.19 | -66.15 | -125.6 | -127.4 | -78.96 | 44.95 | -6.793 | -47.46 |
| Net margin | -33,414.29% | -231.07% | -458.94% | -479.26% | -131.59% | 21.66% | -5.67% | -32.59% |
| EPS 2 | -2.980 | -1.920 | -2.710 | -2.600 | -1.390 | 0.7174 | -0.8096 | -0.8033 |
| Free Cash Flow 1 | -42.4 | -72.96 | -109 | -108.9 | -70.84 | 177 | -34.5 | -78 |
| FCF margin | -18,355.41% | -254.84% | -398.31% | -409.81% | -118.08% | 85.3% | -28.8% | -53.57% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | 393.78% | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 3/10/20 | 3/10/21 | 2/28/22 | 3/15/23 | 2/27/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 10.29 | 8.617 | 25.72 | 0.859 | - | - | - | - | - | 60 | 120 | 60 | - | 9 | - |
| EBITDA 1 | -33.71 | -36.78 | -20.86 | -41.18 | -32.03 | -36.26 | -35.77 | -42.12 | -38.08 | 23.3 | -38 | -38 | -39 | -30 | - |
| EBIT 1 | -33.93 | -37.02 | -21.11 | -41.44 | -32.3 | -36.52 | -36.02 | -42.35 | -38.33 | 23.05 | 36.92 | 30.55 | -40.6 | -30.75 | - |
| Operating Margin | -329.83% | -429.57% | -82.07% | -4,824.56% | - | - | - | - | - | 38.42% | 30.77% | 50.92% | - | -341.67% | - |
| Earnings before Tax (EBT) 1 | -33.8 | -36.91 | -20.93 | -41.04 | -31.23 | -34.19 | -33.72 | -38.46 | -34.1 | 27.34 | 114.2 | -37.05 | -38.4 | -16.75 | - |
| Net income 1 | -33.8 | -36.91 | -20.93 | -41.04 | -31.23 | -34.19 | -33.72 | -38.46 | -34.1 | 27.34 | 39.32 | 32.35 | -38.44 | -28.12 | - |
| Net margin | -328.64% | -428.3% | -81.37% | -4,777.3% | - | - | - | - | - | 45.56% | 32.77% | 53.91% | - | -312.44% | - |
| EPS 2 | -0.7000 | -0.7700 | -0.4300 | -0.8400 | -0.6400 | -0.6900 | -0.6700 | -0.6800 | -0.5800 | 0.4400 | 1.194 | 0.3360 | -0.6341 | -0.5051 | -0.7700 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/3/21 | 2/28/22 | 5/4/22 | 8/4/22 | 11/8/22 | 3/15/23 | 5/4/23 | 8/3/23 | 11/2/23 | 2/27/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 123 | 306 | 327 | 126 | 187 | 388 | 637 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -42.4 | -73 | -109 | -109 | -70.8 | 177 | -34.5 | -78 |
| ROE (net income / shareholders' equity) | - | -36.8% | -43.3% | -49.4% | -28.6% | -49.5% | 16.7% | - |
| ROA (Net income/ Total Assets) | - | -27.6% | -37.4% | -42.8% | -26.1% | -39.6% | 15.1% | - |
| Assets 1 | - | 239.7 | 336.1 | 297.8 | 302.9 | -113.6 | -44.97 | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 0.97 | 0.47 | 1.1 | 0.8 | 0.61 | - | - | - |
| Capex / Sales | 418.61% | 1.65% | 4.02% | 2.99% | 1.02% | - | - | - |
| Announcement Date | 3/10/20 | 3/10/21 | 2/28/22 | 3/15/23 | 2/27/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
25.15
USD
Average target price
43
USD
Spread / Average Target
+70.97%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +9.68% | 1.47B | |
| +1.51% | 42.75B | |
| +8.57% | 41.34B | |
| +49.22% | 41.61B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- PTGX Stock
- Financials Protagonist Therapeutics, Inc.
